ResearcherHarvard UniversityActive in the last 2 years

Pranav Rajpurkar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8030-3727; OpenAlex author ID A5001094226. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Pancreatic Cancer AI: The Need for Prospective Outcome Studies. First author DOI 10.1148/radiol.261539 ↗
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101013 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Rajesh Bhayana · 1 shared paper, 2026 · strength 0.63
- Paper Pancreatic Cancer AI: The Need for Prospective Outcome Studies. DOI 10.1148/radiol.261539 ↗
Davendra P. S. Sohal · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Zev A. Wainberg · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Vivek U. Nimgaonkar · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Arnav Mehta · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Andrew Eugene Hendifar · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Eric Andrew Collisson · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Shalini Makawita · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Julia Sidenius Johansen · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Christos K Fountzilas · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Benjamin Musher · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗
Aatur Dilip Singhi · 1 shared paper, 2023 · strength 0.14
- Paper Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment o… DOI 10.1016/j.xcrm.2023.101013 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.